PGEN
Price
$0.76
Change
+$0.03 (+4.11%)
Updated
Dec 20, 04:59 PM (EDT)
66 days until earnings call
RYTM
Price
$56.03
Change
+$0.55 (+0.99%)
Updated
Dec 20, 04:59 PM (EDT)
72 days until earnings call
Ad is loading...

PGEN vs RYTM

Header iconPGEN vs RYTM Comparison
Open Charts PGEN vs RYTMBanner chart's image
Precigen
Price$0.76
Change+$0.03 (+4.11%)
Volume$12.59K
CapitalizationN/A
Rhythm Pharmaceuticals
Price$56.03
Change+$0.55 (+0.99%)
Volume$22.16K
CapitalizationN/A
PGEN vs RYTM Comparison Chart
Loading...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RYTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PGEN vs. RYTM commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PGEN is a Hold and RYTM is a Hold.

COMPARISON
Comparison
Dec 23, 2024
Stock price -- (PGEN: $0.76 vs. RYTM: $56.12)
Brand notoriety: PGEN and RYTM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PGEN: 197% vs. RYTM: 260%
Market capitalization -- PGEN: $223.34M vs. RYTM: $3.45B
PGEN [@Biotechnology] is valued at $223.34M. RYTM’s [@Biotechnology] market capitalization is $3.45B. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PGEN’s FA Score shows that 0 FA rating(s) are green whileRYTM’s FA Score has 0 green FA rating(s).

  • PGEN’s FA Score: 0 green, 5 red.
  • RYTM’s FA Score: 0 green, 5 red.
According to our system of comparison, RYTM is a better buy in the long-term than PGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PGEN’s TA Score shows that 3 TA indicator(s) are bullish while RYTM’s TA Score has 2 bullish TA indicator(s).

  • PGEN’s TA Score: 3 bullish, 5 bearish.
  • RYTM’s TA Score: 2 bullish, 7 bearish.
According to our system of comparison, PGEN is a better buy in the short-term than RYTM.

Price Growth

PGEN (@Biotechnology) experienced а +12.93% price change this week, while RYTM (@Biotechnology) price change was +1.59% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

PGEN is expected to report earnings on Feb 26, 2025.

RYTM is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RYTM($3.45B) has a higher market cap than PGEN($223M). RYTM YTD gains are higher at: 22.080 vs. PGEN (-43.090). PGEN has higher annual earnings (EBITDA): -136.11M vs. RYTM (-237.01M). RYTM has more cash in the bank: 298M vs. PGEN (28.6M). RYTM has less debt than PGEN: RYTM (4.03M) vs PGEN (5.75M). RYTM has higher revenues than PGEN: RYTM (113M) vs PGEN (3.96M).
PGENRYTMPGEN / RYTM
Capitalization223M3.45B6%
EBITDA-136.11M-237.01M57%
Gain YTD-43.09022.080-195%
P/E RatioN/AN/A-
Revenue3.96M113M4%
Total Cash28.6M298M10%
Total Debt5.75M4.03M143%
FUNDAMENTALS RATINGS
PGEN vs RYTM: Fundamental Ratings
PGEN
RYTM
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
98
Overvalued
PROFIT vs RISK RATING
1..100
10034
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
8745
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
44n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PGEN's Valuation (54) in the null industry is somewhat better than the same rating for RYTM (98) in the Biotechnology industry. This means that PGEN’s stock grew somewhat faster than RYTM’s over the last 12 months.

RYTM's Profit vs Risk Rating (34) in the Biotechnology industry is significantly better than the same rating for PGEN (100) in the null industry. This means that RYTM’s stock grew significantly faster than PGEN’s over the last 12 months.

PGEN's SMR Rating (99) in the null industry is in the same range as RYTM (100) in the Biotechnology industry. This means that PGEN’s stock grew similarly to RYTM’s over the last 12 months.

RYTM's Price Growth Rating (45) in the Biotechnology industry is somewhat better than the same rating for PGEN (87) in the null industry. This means that RYTM’s stock grew somewhat faster than PGEN’s over the last 12 months.

RYTM's P/E Growth Rating (100) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that RYTM’s stock grew similarly to PGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PGENRYTM
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
88%
Bullish Trend 3 days ago
78%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
87%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
78%
Advances
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
81%
Declines
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 10 days ago
79%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
86%
View a ticker or compare two or three
Ad is loading...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RYTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ICEQX21.730.25
+1.16%
Delaware Ivy Core Equity Fund Class R6
HNASX18.740.20
+1.08%
Homestead Growth
AIVSX57.980.59
+1.03%
American Funds Invmt Co of Amer A
EIVPX15.440.15
+0.98%
Parametric Volatil Risk Prm-Defensv I
NGRRX28.400.11
+0.39%
Nuveen International Value I

PGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PGEN has been loosely correlated with CRSP. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if PGEN jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PGEN
1D Price
Change %
PGEN100%
+5.07%
CRSP - PGEN
53%
Loosely correlated
+0.83%
NTLA - PGEN
51%
Loosely correlated
+0.83%
RCKT - PGEN
50%
Loosely correlated
+1.85%
BEAM - PGEN
50%
Loosely correlated
+8.04%
NKTX - PGEN
50%
Loosely correlated
+7.73%
More

RYTM and

Correlation & Price change

A.I.dvisor indicates that over the last year, RYTM has been loosely correlated with RCKT. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if RYTM jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RYTM
1D Price
Change %
RYTM100%
+1.15%
RCKT - RYTM
48%
Loosely correlated
+1.85%
PLRX - RYTM
43%
Loosely correlated
-0.68%
ERAS - RYTM
43%
Loosely correlated
+3.67%
IDYA - RYTM
42%
Loosely correlated
+3.31%
PGEN - RYTM
42%
Loosely correlated
+5.07%
More